We reaffirm that today, given the FDA panel's recommended green light, for its newest mRNA vaccine for various flu strains -- in older adults. It was trading aroung $30; it is now at about $72. . . but $85 a share would be a very fair value, in the next six to 24 months. Here's a bit, from NBC a few weeks back:
. . .If approved, it would be the world’s first messenger RNA flu shot, providing public health officials with a much more nimble tool to fight influenza. In a late-stage trial, the vaccine was found to be about 27% more effective than a standard flu shot. . . .
The Department of Health and Human Services, which oversees the FDA, has been hostile to mRNA technology under Health Secretary Robert F. Kennedy Jr. He’s called the mRNA Covid shot “the deadliest vaccine ever made,” and last year HHS canceled nearly $500 million in funding for mRNA vaccine research.
The path to approval of Moderna’s flu vaccine has been touch-and-go. Earlier this year, the FDA initially refused to even review the company’s application for the shot, before reversing course a week later. . . .
Obviously, idiotic MAGA politics are interfering with public health here -- so we hedge a bit, on whether the jab will reach market before flu season this fall. But the clear scientific arc -- bends toward a material revenue enhancer for Moderna.
Onward.
नमस्ते
No comments:
Post a Comment